Reaction
B-Lymphocyte Count Decreased reporting signals
As of the last recalculation, B-Lymphocyte Count Decreased appears in 1,330 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is OCRELIZUMAB (PRR 198.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ocrelizumab | 495 | 198.4 | 200.0 |
| Ofatumumab | 95 | 48.1 | 48.2 |
| Rituximab | 407 | 43.0 | 43.1 |
| Alemtuzumab | 33 | 27.4 | 27.4 |
| Dalfampridine | 110 | 26.1 | 26.1 |
| Dronabinol | 12 | 23.6 | 23.6 |
| Mesna | 11 | 20.6 | 20.6 |
| Mesna Injection | 10 | 19.1 | 19.1 |
| Bendamustine Hydrochloride | 13 | 17.1 | 17.2 |
| Obinutuzumab | 16 | 15.4 | 15.4 |
| Cladribine | 9 | 14.7 | 14.8 |
| Axicabtagene Ciloleucel | 9 | 14.4 | 14.4 |
| Baclofen | 70 | 13.4 | 13.4 |
| Cyclophosphamide Injection, Solution | 128 | 12.4 | 12.4 |
| Cyclophosphamide | 128 | 12.4 | 12.4 |
| Cyclophosphamide For Injection | 128 | 12.4 | 12.4 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 18 | 12.2 | 12.2 |
| Tizanidine | 18 | 12.0 | 12.0 |
| Amantadine | 10 | 10.2 | 10.2 |
| Modafinil | 20 | 9.8 | 9.8 |
| Triamcinolone Acetonide | 18 | 9.2 | 9.2 |
| Doxorubicin Hydrochloride | 16 | 7.7 | 7.8 |
| Doxorubicin | 41 | 7.4 | 7.4 |
| Remdesivir | 6 | 7.1 | 7.1 |
| Vincristine Sulfate | 13 | 7.0 | 7.0 |
| Baricitinib | 4 | 6.5 | 6.5 |
| Belimumab | 12 | 6.0 | 6.0 |
| Diroximel Fumarate | 4 | 5.3 | 5.3 |
| Blinatumomab | 3 | 4.5 | 4.5 |